Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Biotechnology

Healthcare
$0.84 -2.80%

-$0.04 today

Market cap
$212.10M
Beta
1.51
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.85High $2.09

Volume 1.22M

Average 1.19M

LCTX Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Lineage Cell Therapeutics, Inc.AMEX: LCTX

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables growth accelerates

Q1 FY2026 accounts payables of $1.71M (cash outflow) rose 1529.5% year over year, ahead of the +135.3% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables amounted to 15.6% of revenue in FY2025, down 2.1 pp from a year earlier.
  • Accounts payables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1529.5% holds above the trailing-twelve-month pace of +135.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.71M-169.6% QoQ
Last fiscal yearDec 2025
$2.27M+235.1% YoY
LTMMar 2026
$665K+135.3% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1529.5%——
1 year+235.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
2.27M USD
Year-over-year change
+235.1%
4-year CAGR
-43.1%

Accounts Payables vs competitors

How LCTX compares with its peers on the latest reported figures

  • LCTX's LTM Mar 2026 accounts payables of $665K is the 2nd largest of the 4 companies compared; the peer median is $0.
  • Its year-over-year change of +135.3% is the highest of 3, against a peer median of -68.5%.
  • Accounts payables amounts to 4.5% of revenue for LCTX, versus a peer median of 5.9%.
LCTX Competitors Peer median
Accounts Payables for LCTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$3.13M -60.6%—11.8%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$665K +135.3%—4.5%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$424K -76.4%——
MESOMesoblast LimitedLTM Jun 2026$0 ——0.0%
Peer median (excluding LCTX) $0-68.5%—5.9%

Competitors are the stored peer set for LCTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.27M)(26.35M)(21.49M)(18.61M)(63.53M)
Depreciation & Amortization873K727K692K609K699K
Deferred Income Tax(6M)0(1.8M)0(5.28M)
Stock-Based Compensation3.52M4.29M4.64M5.08M4.75M
Change in Working Capital21.11M18.67M(10.8M)(8.77M)(4.11M)
Accounts Receivables(857K)50.31M(446K)106K(316K)
Inventory(72K)0000
Accounts Payables21.65M(18.7M)(2.3M)(1.68M)2.27M
Other Working Capital308K(12.94M)(8.06M)(7.19M)(6.07M)
Other Non-Cash Items202K3.73M195K(1.4M)48.55M
Operating Cash Flow(23.56M)1.06M(28.57M)(23.09M)(18.92M)
Capital Expenditures(354K)(413K)(674K)(565K)(522K)
Acquisitions (Net)10.09M45.75M000
Purchases of Investments6.02M(53.41M)(16.4M)(8.76M)(14.94M)
Sales of Investments(6.02M)7.67M63.53M7.02M2M
Other Investing Activities14K(45.75M)000
Investing Cash Flow9.75M(46.16M)46.45M(2.31M)(13.46M)
Debt Repayment(20K)(32K)(54K)(54K)(59K)
Common Stock Issued30.87M148K6.63M35.88M27.03M
Common Stock Repurchased(54K)(17K)(37K)(23K)0
Dividends Paid00000
Other Financing Activities6.14M1.53M(37K)58K(16K)
Financing Cash Flow36.93M1.63M6.42M35.86M26.95M
Effect of Forex Changes(20K)(873K)(250K)(95K)396K
Net Change in Cash23.09M(44.34M)24.06M10.36M(5.03M)
Free Cash Flow(23.92M)646K(29.24M)(23.66M)(19.44M)

Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.